uniQure (NASDAQ:QURE) Price Target Raised to $44.00

uniQure (NASDAQ:QURE) had its price target hoisted by Leerink Partners from $26.00 to $44.00 in a report published on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

Several other equities research analysts have also recently issued reports on QURE. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a report on Tuesday. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $20.00 to $52.00 in a research report on Tuesday. Guggenheim reiterated a “buy” rating on shares of uniQure in a research report on Wednesday. The Goldman Sachs Group reduced their price objective on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada lifted their target price on shares of uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.14.

uniQure Stock Up 2.3 %

uniQure stock opened at $15.40 on Wednesday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The stock has a market capitalization of $750.60 million, a PE ratio of -3.10 and a beta of 0.89. The business has a 50 day simple moving average of $6.85 and a 200-day simple moving average of $6.28. uniQure has a 12 month low of $3.73 and a 12 month high of $17.39.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. On average, analysts anticipate that uniQure will post -3.81 EPS for the current fiscal year.

Insider Activity

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. RTW Investments LP acquired a new position in uniQure in the third quarter valued at approximately $49,000. China Universal Asset Management Co. Ltd. raised its position in uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the period. Atria Investments Inc purchased a new stake in uniQure in the third quarter valued at $53,000. Quarry LP acquired a new position in shares of uniQure in the 3rd quarter valued at $58,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of uniQure by 21.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.